



15992 U.S. PTO

**AMSTER
ROTHSTEIN
& EBENSTEIN LLP**

Intellectual Property Law

90 Park Avenue
New York NY 10016

Main 212 336 8000

Fax 212 336 8001

Web www.arelaw.com

Partners

Morton Amster
Jesse Rothstein (1934 - 2003)
Daniel Ebenstein
Philip H. Gottfried
Michael J. Berger
Neil M. Zipkin
Anthony F. Lo Cicero
Kenneth P. George
Abraham Kasdan, Ph.D.
Ira E. Silfin
Chester Rothstein
Craig J. Arnold
Kenneth M. Bernstein

Senior Counsel

Charles R. Macedo
Mark J. Rosenberg
Nancy M. Dodderidge

Of Counsel

Jerry D. Dainow

Associates

Neal L. Rosenberg
Patrick Boland*
Trebzor Lloyd
Joseph M. Casino
John S. Economou

Michael V. Solomita

Holly Pekowsky
Michael P. Kenney
Marion P. Metelski
Max Vern
Dana R. Metes
Karl J. Kolbinger
Brian A. Comack
Richard S. Mandaro
Marc J. Jason
Elie H. Gendloff, Ph.D.
David Mitnick
Charles W. Rath
David A. Boag

Karen J. Bernstein

Matthieu Hausig
Jung S. Hahn
Reiko Kaji
Alan D. Miller, Ph.D.
Hsin-Hsin (Ginger) Liu
John A. Lepore*
Norajean McCaffrey

**Not admitted in New York*

March 18, 2004

Alan D. Miller

Direct 212 336 8094

E-mail amiller@arelaw.com

Via Express Mail

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

"Express Mail" mailing label no.	EL 996377277 US
Date of Deposit:	March 18, 2004
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Name:	Alan D. Miller
Signature:	

Re: New U.S. Patent Application, Continuation-in-Part of
U.S. Patent Application No. 10/752,423, Continuation-
in-Part of U.S. Patent Application No. 10/725,965
Title: METHOD OF TREATING NEURODEGENERATIVE
DISEASES USING D4 AND 5-HT2A ANTAGONISTS,
INVERSE AGONISTS OR PARTIAL AGONISTS
Inventor: Erik Buntinx
Our File: 29248/21

Dear Sir:

Enclosed please find a Continuation-in-Part application in the name of Erik Buntinx, entitled METHOD OF TREATING NEURODEGENERATIVE DISEASES USING D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS OR PARTIAL AGONISTS, including the following:

1. a Utility Patent Application Transmittal sheet (Form PTO/SB/05);
2. a complete utility application, including specification (36 pages); claims (7 pages); abstract (1 page); and
3. a return receipt postcard.

This application is a Continuation-in-Part Application of U.S. Patent Application No. 10/752,423 filed January 6, 2004, which is a Continuation-in-Part of U.S. Application No. 10/725,965 filed December 2, 2003.

March 18, 2004


Please acknowledge receipt of the enclosed papers by stamping the enclosed postcard and returning the same to us.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP
Attorneys for Applicant
90 Park Avenue
New York, New York 10016
(212) 336-8000

Dated: March 18, 2004
New York, New York

By

A handwritten signature in black ink, appearing to read "Alan D. Miller", is written over a horizontal line.

Alan D. Miller, Reg. No. 42,889